Effectivement...., que j'aurais dû ajouter dans mon préambule.
*Martin Chénier*
/[email protected]/
M. Chenier wrote:
C'est pas la seule dans le domaine du contrôle intensif de la glycémie:
http://www.ncbi.nlm.nih.gov/pubmed/18539917?dopt=Abstract
http://www.ncbi.nlm.nih.gov/pubmed/18728267?dopt=Abstract
*M. Chénier*
/[email protected]/
Alain Vadeboncoeur wrote:
Fascinant quand même de nombre d'études qui se publient sur L'ABSENCE
de gains dans divers contextes d'un contrôle serré de la glycémie!
Alain
------------------------------------------------------------------------
*From:* [email protected] [mailto:[email protected]] *On Behalf Of
*Équipe éditoriale de amc.ca
*Sent:* 25 mars 2009 04:00
*To:* [email protected]
*Subject:* InfoPOEM: Intensive glucose control ineffective in ICU
patients
Pour assurer la livraison de ce courriel dans votre boîte de
réception, veuillez ajouter [email protected] <mailto:[email protected]> à
votre carnet de contacts.
Intensive glucose control ineffective in ICU patients
*Clinical question *
Does tight control of blood glucose improve survival of patients in a
medical surgical intensive care unit?
*Bottom line *
Tight control of blood glucose levels -- 80 mg/dL to 110 mg/dL
(4.4-6.1 mmol/L) -- did not decrease mortality or other measured
outcomes in patients admitted to an intensive care unit (ICU) with
hyperglycemia. Hypoglycemia was much more common and was associated
with an increased mortality. A meta-analysis has found similar
results. (LOE = 1b) <http://mailer.cma.ca/t/4155251/234493/102001/0/>
*Reference *
Arabi YM, Dabbagh OC, Tamim HM, et al. Intensive versus conventional
insulin therapy: A randomized controlled trial in medical and
surgical critically ill patients. Crit Care Med
2008;36(12):3190-3197.
<http://mailer.cma.ca/t/4155251/234493/4597965/0/>
*Study design*
Randomized controlled trial (nonblinded)
*Funding*
Foundation
*Allocation*
Concealed
*Setting*
Inpatient (ICU only)
Obtenez des crédits
Mainpro <http://mailer.cma.ca/t/4155251/234493/4598439/0/>
Discutez de cet
InfoPOEM <http://mailer.cma.ca/t/4155251/234493/4597967/0/>
Archives <http://mailer.cma.ca/t/4155251/234493/145011/0/>
Bilan des crédits <http://mailer.cma.ca/t/4155251/234493/177011/0/>
Plus de FMC / DPC <http://mailer.cma.ca/t/4155251/234493/3021/0/>
<http://mailer.cma.ca/t/4155251/234493/196001/0/>
Publicité
Bibliothécaire de l'AMC
<http://mailer.cma.ca/t/4155251/234493/147004/0/>
Envoyez-nous vos commentaires <mailto:[email protected]>
*Synopsis *
The Saudi Arabian investigators conducting this study enrolled 523
adults in a medical surgical ICU. The unit was closed and covered at
all times by an intensivist. The patients (75% men) did not have type
1 diabetes, though 40% had a history of type 2 diabetes. The average
blood glucose level was 194 mg/dL (10.8 mmol/L) in the intensive
insulin group and 210 mg/dL (11.7 mmol/L) in the conventional insulin
group. Most of the patients were nonoperative and were critically
ill; 85% were mechanically ventilated and 65% were receiving
vasopressors, with a mortality rate was approximately 15%. All
patients received an infusion of regular insulin and were randomly
assigned, using concealed allocation, to have their blood glucose
maintained at 80 mg/dL to 110 mg/dL (4.4 - 6.1 mmol/L) in the
intensive insulin group and 180 mg/dL to 200 mg/dL (10.0-11.1 mmol/L)
in the conventional treatment group. Analysis was by intention to
treat. The main outcome, in-ICU mortality, was not different between
the 2 groups. At least one episode of hypoglycemia occurred in 28.6%
of patients in the tight control group and 3.1% of patients in the
conventional treatment group. In-ICU mortality was higher among those
who had hypoglycemia (23.8% vs 13.7%; P = .02). There was no
difference in in-hospital mortality, ICU or hospital length of stay,
ventilation duration, infections, or the need for transfusion. These
results are similar to those found in a previous meta-analysis (JAMA
2008;300(8):933-944).
Discutez de cet InfoPOEM
<http://mailer.cma.ca/t/4155251/234493/4597967/0/>
*Archives*
InfoPOEMs (contenu anglais)
<http://mailer.cma.ca/t/4155251/234493/145011/0/> | CLIPs (contenu
anglais) <http://mailer.cma.ca/t/4155251/234493/322001/0/> | Critique
et pratique <http://mailer.cma.ca/t/4155251/234493/177003/0/>
*Ressources cliniques*
Accueil <http://mailer.cma.ca/t/4155251/234493/94016/0/> | Manuels *
<http://mailer.cma.ca/t/4155251/234493/177004/0/> | Revues *
<http://mailer.cma.ca/t/4155251/234493/177005/0/> | Information
médicaments * <http://mailer.cma.ca/t/4155251/234493/145012/0/> |
Tests de laboratoire *
<http://mailer.cma.ca/t/4155251/234493/128015/0/> | InfoPOEMs
<http://mailer.cma.ca/t/4155251/234493/145011/0/> | Guide de pratique
clinique <http://mailer.cma.ca/t/4155251/234493/324016/0/> |
Documents d'information pour les patients *
<http://mailer.cma.ca/t/4155251/234493/177007/0/> | Bibliothécaire de
l'AMC * <http://mailer.cma.ca/t/4155251/234493/147004/0/>
*Raccourcis*
MD Consult * <http://mailer.cma.ca/t/4155251/234493/145015/0/> |
STAT!Ref * <http://mailer.cma.ca/t/4155251/234493/148015/0/> |
[email protected] * <http://mailer.cma.ca/t/4155251/234493/177008/0/> | OVID
Medline * <http://mailer.cma.ca/t/4155251/234493/145016/0/> | Revues
EBSCO * <http://mailer.cma.ca/t/4155251/234493/145014/0/> | JAMC
<http://mailer.cma.ca/t/4155251/234493/177009/0/> | Essential
Evidence Plus <http://mailer.cma.ca/t/4155251/234493/138018/0/>|
MedCalc 3000 * <http://mailer.cma.ca/t/4155251/234493/177010/0/>
*FMC / DPC*
Voir les cours en ligne
<http://mailer.cma.ca/t/4155251/234493/3021/0/> | Bilan des crédits
<http://mailer.cma.ca/t/4155251/234493/177011/0/>
*Gestion de la pratique*
Accueil <http://mailer.cma.ca/t/4155251/234493/77020/0/> | Créez un
site Web de pratique <http://mailer.cma.ca/t/4155251/234493/140/0/> |
Clinique informatisée
<http://mailer.cma.ca/t/4155251/234493/234014/0/> | Bureau
<http://mailer.cma.ca/t/4155251/234493/234015/0/> | Dotation en
personnel <http://mailer.cma.ca/t/4155251/234493/234016/0/> |
Finances <http://mailer.cma.ca/t/4155251/234493/234017/0/> |
Juridique et vie privée <http://mailer.cma.ca/t/4155251/234493/234018/0/>
* Service aux membres AMC
POEMs veut dire "Patient-Oriented Evidence that Matters".
Désirez-vous changer le format de vos courriels d'InfoPOEMs
quotidiens ou votre adresse courriel de la liste d'InfoPOEMs quotidiens?
Gérez vos options d'InfoPOEMs quotidiens
<http://mailer.cma.ca/t/4155251/234493/3026/0/> à partir du site Web
amc.ca.
Cliquez ici pour vous désabonner
<http://mailer.cma.ca/u?id=234493.2ee32010d4b1d8089bbf2b767ebd5713&o=4155251&u=http://www.cma.ca/index.cfm/ci_id/324/la_id/2.htm&w=F&a=T&c=F&l=poem>.
Copyright © 1995-2009 InfoPOEM, Inc. www.infopoems.com
<http://mailer.cma.ca/t/4155251/234493/3966545/0/>. Tous droits
réservés.
Copyright © 2009 Association Médicale Canadienne, Tous droits réservés.